Breast Cancer Clinical Trial

A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)

Summary

This is a multicenter, open-label study in participants with triple negative breast cancer (TNBC) to study the safety, tolerability, pharmacokinetics and preliminary efficacy of SC-005. This study consists of 2 parts: Part A (dose regimen finding) followed by Part B (dose expansion).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically or cytologically confirmed advanced TNBC that is relapsed, refractory, or progressive and not eligible for another standard therapy that would confer clinical benefit to the subject.

Advanced disease is defined as metastatic disease or locally advanced disease that is not amenable to surgery or radiotherapy with curative intent
TNBC is defined as:
<1% staining by immunohistochemistry (IHC) for estrogen (ER) and progesterone (PR) receptors, 0 or 1+ IHC for human epidermal growth factor receptor 2 (HER2), OR
Negative for HER2 amplification by in situ hybridization (ISH) for 2+ IHC disease.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Adequate hematologic, hepatic, and renal function.

Exclusion Criteria:

Any significant medical condition including any suggested by Screening laboratory findings that, in the opinion of the Investigator or Sponsor, may place the subject at undue risk from the study.
Has ECG abnormalities that make QT interval corrected (QTc) evaluation difficult (e.g., severe morphologic abnormalities).
Prior exposure to a pyrrolobenzodiazepine or indolino-benzodiazepine based drug, or known hypersensitivity or contraindication to SC-005 or excipient contained in the drug formulation.

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

2

Study ID:

NCT03316794

Recruitment Status:

Terminated

Sponsor:

AbbVie

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 7 Locations for this study

See Locations Near You

University of Chicago /ID# 169231
Chicago Illinois, 60637, United States
Washington University School /ID# 169177
Saint Louis Missouri, 63108, United States
Memorial Sloan Kettering /ID# 201016
New York New York, 10065, United States
Gabrail Cancer Center Research /ID# 168756
Canton Ohio, 44718, United States
Oklahoma University /ID# 200937
Oklahoma City Oklahoma, 73104, United States
Tennessee Oncology-Sarah Cannon Research Institute /ID# 169233
Nashville Tennessee, 37203, United States
Baylor University /ID# 169860
Houston Texas, 77030, United States
MD Anderson Cancer Center /ID# 169232
Houston Texas, 77030, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

2

Study ID:

NCT03316794

Recruitment Status:

Terminated

Sponsor:


AbbVie

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider